Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3865920 | 0.99 | MAPT (0.58) | MAPTNPC1CYP1A2CYP2C19RAB9A | |
| SCHEMBL3863467 | 0.99 | MAPT (0.58) | MAPTNPC1CYP1A2CYP2C19RAB9A | |
| SCHEMBL3863733 | 0.98 | MAPT (0.56) | MAPTNPC1CYP1A2CYP2C19RAB9A | |
| SCHEMBL3863032 | 0.88 | MAPT (0.57) | MAPTNPC1CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL3862354 | 0.86 | MAPT (0.62) | MAPTNPC1CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL3863470 | 0.86 | MAPT (0.52) | MAPTNPC1CYP1A2CYP2C19RAB9A | |
| SCHEMBL3863940 | 0.85 | MAPT (0.61) | MAPTNPC1CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL3863835 | 0.85 | MAPT (0.61) | MAPTNPC1CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL3864891 | 0.84 | MAPT (0.54) | MAPTNPC1CYP1A2CYP2C19RAB9A | |
| SCHEMBL3863737 | 0.84 | MAPT (0.59) | MAPTNPC1CYP1A2CYP2C19RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7601856-B2 | Benzofurans as potassium ion channel modulators | WYETH (US) | 2009-10-13 | — | — | US | claimed |
| US-20080027049-A1 | Such as 2,2-Dimethyl-N-(6,7,8,9-tetrahydro-dibenzofuran-2-yl)-propionamide | WYETH (US) | 2008-01-31 | — | — | US | claimed |
| US-7601856-B2 | Benzofurans as potassium ion channel modulators | WYETH (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601856-B2 | Benzofurans as potassium ion channel modulators | WYETH (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601856-B2 | Benzofurans as potassium ion channel modulators | WYETH (US) | 2009-10-13 | — | — | US | disclosed |
| US-20080027049-A1 | Such as 2,2-Dimethyl-N-(6,7,8,9-tetrahydro-dibenzofuran-2-yl)-propionamide | WYETH (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027049-A1 | Such as 2,2-Dimethyl-N-(6,7,8,9-tetrahydro-dibenzofuran-2-yl)-propionamide | WYETH (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027049-A1 | Such as 2,2-Dimethyl-N-(6,7,8,9-tetrahydro-dibenzofuran-2-yl)-propionamide | WYETH (US) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027049-A1 | Such as 2,2-Dimethyl-N-(6,7,8,9-tetrahydro-dibenzofuran-2-yl)-propionamide | KCNJ2, KCNJ5, KCNA5 | MAPT 2740/4885NPC1 1260/4885CYP1A2 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.